Date: 2014-10-22
Type of information: Private placement
Company: Hybrigenics (France)
Investors: Crede Capital Group (USA)
Amount: €4.62 million
Funding type: private placement
Planned used: Hybrigenics will use this financing to strengthen its research and clinical development activities.
Others: * On October 22, 2014, Hybrigenics, a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in proteomic and genomic scientific services, announced the successful completion of a private placement for €4.62 million to the Crede Capital Group, a US-based family office, which has completed numerous investments in European life sciences companies.
A total of 3,500,000 new shares have been issued at €1.32 each, representing a 20% discount to the 5-day volume weighted average price of Hybrigenics shares prior to the operation which was completed on the basis of the delegation in place according to the 11th resolution voted by the Shareholders’ Meeting of June 20, 2014 with respect to private placements to qualified investors or to a small number of investors with the meaning of the paragraph II of article L. 411-2 of the French financial and monetary Code. The new shares are of the same class as existing shares and represent 13.5% of Hybrigenics’ capital before the capital raise and 11.9% after.
Therapeutic area: Technology - Services - Cancer - Oncology
